Injection works begin to protect 1,400 city trees
Brighton & Hove City Council said it would inject hundreds of trees with a non-toxic substance designed to protect elm trees from the disease.
The council said it was expanding the programme, now in its third year, to include more trees and parks.
Inoculation works will last around two weeks and take place across the city including in Old Steine, Pavilion Gardens and Valley Gardens.
New areas to be targeted in this year's programme include Queen's Park, Wish Park and St Ann's Well Gardens.
Elm disease, which is caused by a fungus and spread by elm bark beetles, has killed millions of trees in the UK over the past 50 years, according to the Woodland Trust.
Follow BBC Sussex on Facebook, on X, and on Instagram. Send your story ideas to southeasttoday@bbc.co.uk or WhatsApp us on 08081 002250.
Tree inoculation aims to tackle disease spread
Brighton & Hove City Council
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscape Designed to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight loss Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. ('Nxera'; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders. Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in these major disorders. Chris Cargill, President and CEO of Nxera, commented: 'Nxera scientists were among the pioneers in elucidating the structure of the GLP-1 receptor and other key receptors being targeted, giving us a clear advantage in developing potentially best-in-class next generation drug candidates. For the past 12 months, Nxera scientists have been advancing a broad metabolic disease pipeline to capitalize independently on our differentiated science. Today, we reveal the addition of these programs to our discovery portfolio, and are confident in achieving significant progress over the mid-term, delivering clear value for shareholders and patients in the rapidly expanding obesity market, projected to exceed US$100 billion annually in global sales.' Central to Nxera's pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from Pfizer's PF-06954522, allowing Nxera full control to drive rapid progress. Complementing this program, Nxera is simultaneously accelerating the advancement of an additional six established GPCR-targeted programs focused on obesity and chronic weight management: Three small molecule agonist programs (GIP, Apelin, Amylin) One small molecule antagonist program (GIP) Two long-acting programs (targets undisclosed) Nxera's pipeline leverages its proprietary NxWave™ GPCR-focused structure-based design platform to rapidly identify unique, highly differentiated lead molecules with novel chemistry. This process utilizes Nxera's NxHit proprietary small molecule libraries and NxStaR proteins for DNA encoded library (DEL) screening, distinguishing these candidates from others currently in discovery and clinical development globally. Nxera's focused approach is designed to deliver highly effective therapies addressing critical patient needs: Long-term weight maintenance: Convenient, scalable oral therapies for sustained weight loss. Targeting key obesity-related co-morbidities: Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously. Reducing side effects and broadening out to difficult to treat populations: Targeted treatments for elderly, post-menopausal, and sarcopenic populations. Backed by an expert team with deep experience in GPCR drug discovery, Nxera is strategically positioned to be a leader in developing the next generation of best-in-class obesity and metabolic therapies. Nxera maintains its strong commitment to other key therapeutic areas including neurology, gastroenterology, and immunology, continuing to leverage the NxWave™ platform's proven capabilities in these domains. Separately, Nxera notes that Pfizer yesterday discontinued development of its Phase 1 candidate PF-06954522, a separate small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera. This discontinuation by Pfizer was due to a portfolio decision and not because of any adverse safety findings. Nxera intends to enter discussions with Pfizer regarding potential opportunities to advance GLP-1 molecules discovered by Pfizer under the collaboration. Nxera will announce its earnings results and present operational highlights for Q2 2025 on Friday, 8 August 2025. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5962 5718 | +44 (0)1223 949390 |IR@ MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@ Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or in to access your portfolio
Yahoo
40 minutes ago
- Yahoo
Treatment for advanced womb cancer ‘major step forward'
Women with advanced form womb cancer have been given fresh hope after a new treatment was given the green light for widespread NHS use. Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'
Yahoo
40 minutes ago
- Yahoo
Wes Streeting warned alcohol measures ‘are not sufficient' to stop harm
Government plans to tackle problem drinking 'are not sufficient to address the scale and complexity of harm', leading health experts have warned. Academics, medics and charities from around the country have urged ministers to take 'ambitious' action to tackle the 'scale of the current crisis'. The Government recently set out plans to improve the health of people in England over the next decade. But in a letter to Health Secretary Wes Streeting, shared with the PA news agency, experts said that the public 'want and deserve' more action to tackle the harms. 'As experts from across alcohol policy, health and treatment, we urge you to revisit the current approach to tackling alcohol harm and commit to an ambitious, evidence-based strategy that reflects the scale of the current crisis,' the letter states. 'The 10-Year health plan for England offered a once-in-a-generation opportunity to shift gear and deliver genuine preventative action that would reverse the rising rates of alcohol-related hospitalisations and deaths we have seen in recent years. 'While the introduction of mandatory alcohol labelling and increased support for community-led schemes is welcome, these measures alone are not sufficient to address the scale and complexity of harm.' The letter has been signed by 34 health leaders from leading health organisations including the Alcohol Health Alliance; the Royal College of Physicians; the Royal College of General Practitioners and the Royal College of Emergency Medicine. The 10 Year Health Plan for England, which was published last month, sets out plans to tackle harmful drinking through alcohol labelling, which will include health warning messages. The document also sets out proposed changes to no and low (NoLo) alcohol products and pledged support for community-led schemes to reduce alcohol harm. Before the 10 Year Plan was released there was speculation over whether the plan would include a ban on alcohol advertising. It was also reported that ministers were exploring the possibility of minimum unit pricing (MUP), a policy which sets the lowest price an alcoholic drink can be sold for. In the new letter, experts have called for a series of measures to tackle alcohol harms, including: – A call for the introduction of MUP in England, as seen in Scotland and Wales. – Giving local authorities the power to regulate hours of sale and online deliveries of alcohol. – For advertising regulations for alcohol to be 'aligned' with those for foods high in fat, salt and sugar. – A change to alcohol tax, linking duties to inflation and ending 'cider exceptionalism'. – More funding and support for local alcohol care teams. The group stresses that 'alcohol is not just the problem of a few'. It points out that every year alcohol contributes to more than a million hospital admissions. And the experts said that across the UK, 30% of the adult population engage in 'risky drinking', and almost one in 25 of all new cancers are estimated to be linked to alcohol. The 10 Year Plan states: 'While many people enjoy a drink in moderation, 4% of people drink as much as 30% of alcohol consumed each year.' But it adds that the estimated total 'societal cost' of alcohol harm in England was £27.4 billion per year in 2021/22. The authors conclude: 'The public want and deserve action, and we stand ready to work with Government to deliver real progress. 'By taking meaningful and co-ordinated action now, the burden of alcohol harm can fall significantly within the term of this Government, with visible results for families, the NHS, crime, and the economy.' The Department of Health and Social Care said it will continue to consider the most effective interventions to reduce alcohol harms. A spokesperson said: 'As we shift from sickness to prevention through our 10-Year Health Plan, we will make it mandatory for alcoholic drinks to display health warnings and nutritional information. 'To improve drug and alcohol treatment services and recovery support in England, the Government has also provided an additional £310 million in 2025/26, on top of the public health grant.' A spokesperson for the Portman Group said: 'Whilst overall alcohol consumption and harms such as binge drinking, underage drinking and anti-social behaviour continue to fall, and the vast majority of people drink within the chief medical officer's low-risk guidance or not at all, we share concerns around rising deaths and those who continue to drink to harmful levels. 'We support further targeted and tailored measures aimed at this group to manage the complex, often interrelated issues underlying harmful consumption and back calls for the further rollout of alcohol care teams and greater integration of care pathways. 'As the alcohol industry regulatory body for marketing, we welcome the chance to work constructively with the Government on the proposals within its 10 year plan to help more consumers make an informed choice and drink moderately.' – Other signatories on the letter include representatives from: the Institute of Alcohol Studies; Alcohol Change UK; the Royal College of Surgeons of England; the Royal Society for Public Health; the British Society of Gastroenterology; World Cancer Research Fund; the Association of Anaesthetists; the Association of Directors of Public Health; the British Association for the Study of the Liver; the Medical Council on Alcohol and the British Medical Association.
